GlaxoSmithKline has buyers interested in taking the diet drug Alli off its hands, if Roche could just get its manufacturing issues fixed.
GlaxoSmithKline's ($GSK) good news: It has found a buyer for European rights to a portfolio of consumer products it has been trying to unload for some time. The not-so-good: It's still stuck with Alli, the weight-loss drug, as supply problems weigh on its ability to market the brand.
Omega Pharma will get GlaxoSmithKline's ($GSK) manufacturing plant in Herrenberg, Germany, as part of the $612 million acquisition of GSK's over-the-counter healthcare brands in Europe.
GlaxoSmithKline ($GSK) wants to make a deal already. After hawking a portfolio of consumer drugs for months, the company managed to unload 17 of them to Prestige Brands Holdings in December. Now, it
GlaxoSmithKline ($GSK) can thank Greece and Angela Merkel if its attempt to sell an OTC drug portfolio stalls. Europe's inability to get its act together is frustrating some M&A, as satisfactory
Shengyang Zhou, of Yunnan, China, has been given 87 months in federal prison and fined more than $500,000. Zhou pleaded guilty in January to trafficking and importing counterfeit Alli, the
The FDA is slapping new liver-injury warnings on the weight-loss drugs Xenical and Alli. The decision comes after a safety review at the agency, prompted by reports of liver problems among patients
Drug giant GlaxoSmithKline is fighting counterfeiters who have targeted its over-the-counter weight-loss product, Alli. The fakes contain sibutramine rather than the drug's active ingredient,
No sooner had GlaxoSmithKline been hit with H1N1 flu disappointments than another problem surfaced: counterfeit versions of its weight-loss product Alli. The difference is that the flu vaccine and
Glaxo goes to Hollywood. The company is producing a "hard-hitting" documentary to educate folks about obesity--and increase awareness of its weight-loss drug Alli, the New York Times reports. An